Avoiding common traps in drug development
LU Bio has identified important trends and common traps in drug development. Based on those observations, a business model has been established that differs from those of most other drug developers’. Decisive pruning according to pre-set tollgate criteria during the development process is an instrumental part of LU Bio’s model to decrease risk.
LU Bio’s business model comprises of three corner stones:
-Secure access to top notch university projects,see the Portfolio Companies (PCs) here
-Develop projects in a professional and cost efficient manner with optimal strategies for product as well as commercial development
-Exit or only commercial efforts after preclinical stage
You can contact us here